Healthy volunteers test new Drug's safety in Early-Stage trial
NCT ID NCT06243198
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This study tested the safety and side effects of a single dose of lebrikizumab (given as a shot under the skin) compared to a placebo in 24 healthy Chinese adults. Researchers also measured how fast the drug enters the blood and how long it stays in the body. The study did not aim to treat any disease, but to gather early safety information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.